Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
- 1 May 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 63 (5) , 951-957
Abstract
Dipeptidyl peptidase-4 inhibitors prevent the degradation of incretin hormones and reduce postprandial hyperglycemia in patients with type 2 diabetes mellitus. Dipeptidyl peptidase-4 degrades other peptides with a penultimate proline or alanine, including bradykinin and substance P, which are also substrates of angiotensin-converting enzyme (ACE). During ACE inhibition, substance P is inactivated primarily by dipeptidyl peptidase-4, whereas bradykinin is first inactivated by aminopeptidase P. This study tested the hypothesis that dipeptidyl peptidase-4 inhibition potentiates vasodilator and fibrinolytic responses to substance P when ACE is inhibited. Twelve healthy subjects participated in this randomized, double-blinded, placebo-controlled crossover study. On each study day, subjects received sitagliptin 200 mg by mouth or placebo. Substance P and bradykinin were infused via brachial artery before and during intra-arterial enalaprilat. Sitagliptin and enalaprilat each reduced forearm vascular resistance and increased forearm blood flow without affecting mean arterial pressure, but there was no interactive effect of the inhibitors. Enalaprilat increased bradykinin-stimulated vasodilation and tissue plasminogen activator release; sitagliptin did not affect these responses to bradykinin. The vasodilator response to substance P was unaffected by sitagliptin and enalaprilat; however, substance P increased heart rate and vascular release of norepinephrine during combined ACE and dipeptidyl peptidase-4 inhibition. In women, sitagliptin diminished tissue plasminogen activator release in response to substance P both alone and during enalaprilat. Substance P increases sympathetic activity during combined ACE and dipeptidyl peptidase-4 inhibition.Clinical Trial Registration:—: URL:http://www.clinicaltrials.gov. Unique identifier: NCT01413542.Keywords
This publication has 54 references indexed in Scilit:
- Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic PatientsJournal of the American Heart Association, 2013
- Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 DiabetesDiabetes Care, 2011
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in HumansHypertension, 2010
- EFFECTS OF DIPEPTIDYL PEPTIDASE IV INHIBITION ON ARTERIAL BLOOD PRESSUREClinical and Experimental Pharmacology and Physiology, 2007
- Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in MenArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Intra‐arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerabilityBritish Journal of Clinical Pharmacology, 1997
- Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzymePeptides, 1991
- Pharmacological Properties of the Tachykinin Receptor Subtype in the Endothelial Cell and VasodilationAnnals of the New York Academy of Sciences, 1991
- Capsaicin induces a depletion of calcitonin gene-related peptide (CGRP)-immunoreactive nerves in the cardiovascular system of the guinea pig and ratJournal of the Autonomic Nervous System, 1986
- Neuropeptides Contained in Peripheral Cardiovascular NervesClinical and Experimental Hypertension. Part A: Theory and Practice, 1984